Keylicon Biosciences

Keylicon Biosciences is a private, pre-clinical stage biotech advancing a self-amplifying RNA (saRNA) platform for durable vaccines and therapeutics. The company's core technology is designed to produce more sustained and potent immune responses or protein replacement compared to standard mRNA, potentially improving efficacy and dosing regimens. Operating from San Diego, Keylicon is positioned in the rapidly evolving RNA therapeutics sector, targeting significant unmet needs in infectious diseases and beyond. As a platform-focused company, it is likely seeking partnerships and funding to advance its pipeline.

Next-generation self-amplifying RNA (saRNA) platform designed for durable and potent protein expression from lower doses, intended for vaccines and therapies.

Keylicon competes in the rapidly advancing field of self-amplifying RNA, which includes public companies like Arcturus Therapeutics and Gritstone Bio, as well as private players like Replicate Bioscience. Large pharma, including GSK and Sanofi, also have active saRNA programs and partnerships, creating a crowded and well-resourced competitive environment.